DaShenLin Pharmaceutical Group Co (SHSE:603233) Beneish M-Score: -3.11 (As of Jun. 29, 2026)


SHSE:603233 DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
95 GF Score
Price ¥15.48
GF Value ¥18.69
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is DaShenLin Pharmaceutical Group Co Beneish M-Score?

DaShenLin Pharmaceutical Group Co SHSE:603233 95 Beneish M-Score is -3.11 as of Jun. 29, 2026. GuruFocus rates SHSE:603233 with a GF Score™ of 95/100 and a GF Value™ of ¥18.69 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 630 Healthcare Providers & Services companies, DaShenLin Pharmaceutical Group Co ranks better than 81.9% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.11 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for DaShenLin Pharmaceutical Group Co's Beneish M-Score or its related term are showing as below:

SHSE:603233' s Beneish M-Score Range Over the Past 10 Years
Min: -3.23   Med: -2.74   Max: -1.61
Current: -3.11

During the past 13 years, the highest Beneish M-Score of DaShenLin Pharmaceutical Group Co was -1.61. The lowest was -3.23. And the median was -2.74.


DaShenLin Pharmaceutical Group Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for DaShenLin Pharmaceutical Group Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaShenLin Pharmaceutical Group Co Beneish M-Score Chart

DaShenLin Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.80 -2.84 -2.56 -2.84 -3.23

DaShenLin Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.83 -3.09 -3.00 -3.23 -3.11

DaShenLin Pharmaceutical Group Co Beneish M-Score Competitor Comparison

For the Pharmaceutical Retailers subindustry, DaShenLin Pharmaceutical Group Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DaShenLin Pharmaceutical Group Co Beneish M-Score vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DaShenLin Pharmaceutical Group Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where DaShenLin Pharmaceutical Group Co's Beneish M-Score falls into.


SHSE:603233
95GF Score
DaShenLin Pharmaceutical Group Co Ltd SHSE:603233
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DaShenLin Pharmaceutical Group Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of DaShenLin Pharmaceutical Group Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9375+0.528 * 0.989+0.404 * 0.9711+0.892 * 1.0307+0.115 * 1
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.1209+4.679 * -0.121647-0.327 * 0.9696
=-3.11

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Total Receivables was ¥1,704 Mil.
Revenue was 6973.248 + 7433.943 + 6545.673 + 6566.57 = ¥27,519 Mil.
Gross Profit was 2513.509 + 2450.739 + 2273.031 + 2281.426 = ¥9,519 Mil.
Total Current Assets was ¥13,878 Mil.
Total Assets was ¥26,830 Mil.
Property, Plant and Equipment(Net PPE) was ¥6,642 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,355 Mil.
Total Current Liabilities was ¥14,968 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2,611 Mil.
Net Income was 511.142 + 154.25 + 282.831 + 338.167 = ¥1,286 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = ¥0 Mil.
Cash Flow from Operations was 967.848 + 1621.077 + 818.691 + 1142.588 = ¥4,550 Mil.
Total Receivables was ¥1,763 Mil.
Revenue was 6956.003 + 6765.538 + 6385.657 + 6593.427 = ¥26,701 Mil.
Gross Profit was 2432.94 + 2253.811 + 2184.919 + 2262.562 = ¥9,134 Mil.
Total Current Assets was ¥13,200 Mil.
Total Assets was ¥26,776 Mil.
Property, Plant and Equipment(Net PPE) was ¥7,091 Mil.
Depreciation, Depletion and Amortization(DDA) was ¥0 Mil.
Selling, General, & Admin. Expense(SGA) was ¥1,173 Mil.
Total Current Liabilities was ¥13,660 Mil.
Long-Term Debt & Capital Lease Obligation was ¥4,434 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(1703.883 / 27519.434) / (1763.384 / 26700.625)
=0.061916 / 0.066043
=0.9375

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(9134.232 / 26700.625) / (9518.705 / 27519.434)
=0.342098 / 0.34589
=0.989

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (13878.16 + 6641.907) / 26830.178) / (1 - (13200.482 + 7090.553) / 26776.018)
=0.235187 / 0.242194
=0.9711

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=27519.434 / 26700.625
=1.0307

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(0 / (0 + 7090.553)) / (0 / (0 + 6641.907))
=0 / 0
=1

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(1355.194 / 27519.434) / (1173.077 / 26700.625)
=0.049245 / 0.043934
=1.1209

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((2611.087 + 14967.965) / 26830.178) / ((4433.556 + 13659.582) / 26776.018)
=0.655197 / 0.675722
=0.9696

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(1286.39 - 0 - 4550.204) / 26830.178
=-0.121647

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

DaShenLin Pharmaceutical Group Co has a M-score of -3.11 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -3.11 mean?
DaShenLin Pharmaceutical Group Co (SHSE:603233) has a Beneish M-Score of -3.11 as of Jun. 29, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. According to the industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #114 out of 630 companies in the Healthcare Providers & Services industry, placing it in the top 18.1%.
Is DaShenLin Pharmaceutical Group Co's Beneish M-Score too high?
DaShenLin Pharmaceutical Group Co's current Beneish M-Score is -3.11. Based on the distribution chart, DaShenLin Pharmaceutical Group Co ranks #114 out of 630 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, DaShenLin Pharmaceutical Group Co has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does DaShenLin Pharmaceutical Group Co's Beneish M-Score compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, DaShenLin Pharmaceutical Group Co ranks #114 out of 630 companies for Beneish M-Score. This places DaShenLin Pharmaceutical Group Co in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Healthcare Providers & Services company?
A good Beneish M-Score depends on the Healthcare Providers & Services industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on DaShenLin Pharmaceutical Group Co and its competitors. DaShenLin Pharmaceutical Group Co's current Beneish M-Score is -3.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DaShenLin Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co (SHSE:603233) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥18.69, compared to a current price of ¥15.48 — trading 17.2% below its estimated fair value. The current Beneish M-Score is -3.11. DaShenLin Pharmaceutical Group Co's overall GF Score™ is 95/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For DaShenLin Pharmaceutical Group Co (SHSE:603233), the current Beneish M-Score is -3.11 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is DaShenLin Pharmaceutical Group Co (SHSE:603233) Overvalued in 2026?

Based on GuruFocus' analysis, DaShenLin Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥15.48 is trading 17.2% below its estimated GF Value™ of ¥18.69. GuruFocus considers DaShenLin Pharmaceutical Group Co to be Modestly Undervalued.

Key valuation signals for SHSE:603233:

  • Beneish M-Score: -3.11
  • GF Value™: ¥18.69 vs. price of ¥15.48 (17.2% below fair value)
  • GF Score™: 95/100 with 4 warning signs

No single metric tells the full story. See the SHSE:603233 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


DaShenLin Pharmaceutical Group Co Business Description

Address No. 410-1, Longxi Avenue, Liwan District, Guangdong Province, Guangzhou, CHN, 510000
DaShenLin Pharmaceutical Group Co Ltd is engaged in the pharmaceutical manufacturing, retail, and wholesale business. The company is based on the development of the pharmacy chain. It primarily offers Chinese herbal medicine such as antibiotics and biochemical drugs. The business activities are geographically carried out through China.
95GF Score

Get the complete analysis for SHSE:603233

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥15.48
Price
¥18.69
GF Value